Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
- Registration Number
- NCT06124677
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD), who were previously treated with aflibercept (Eylea®) and had persisting intraretinal or subretinal fluid despite frequent treatments.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients Faricimab Patients who received intravitreal faricimab injections between May and September, in 2023. and conform the inclusion/exclusion criteria.
- Primary Outcome Measures
Name Time Method Proportion of patients responding to the treatment switch 4 weeks Defined as reduction or disappearance of the intra- or subretinal fluid at 4 weeks following a single injection of faricimab
- Secondary Outcome Measures
Name Time Method Durability of a single injection in cases of favorable treatment response without residual fluid Up to 16 weeks Time of reappearance of the fluid
Differences in patient characteristics between individuals responding and not responding to faricimab 4 weeks Changes in visual acuity after the treatment switch 4 weeks Changes in central retinal thickness after the treatment switch 4 weeks Measured on optical coherence tomography (OCT) scans
Changes in pigment epithelium detachment (PED) height after the treatment switch 4 weeks Measured on optical coherence tomography (OCT) scans
Trial Locations
- Locations (1)
Miklos Schneider
🇩🇰Glostrup, Denmark